Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

DO AUG 14 PK 1:13

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

I. Registrans Name		
Alcalde & Fay		
	Suite 850 VA 22201 USA	
3. Principal Place of Business (if different from line 2)		
Gty State/Zip (or Country)	· · · · · · · · · · · · · · · · · · ·	
	ii (apituzi) S. Senaje ID € do@alcalde-fay.com	
7. Client Name 🗀 Self	6. House ID #	
AstraZeneca, A Unit of Zeneca Inc.	31771086	
Check if this filing amends a previously filed version of this: 0. Check if this is a Termination Report □ >> Termination INCOME OR EXPENSES - Complete Either	n Date 11. No Lobbying Activity	
12. Lobbying Firms	13. Organizations	
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:	
Less than \$10,000 (1)	Less than \$10,000 🗀	
\$10,000 or more	\$10,000 or more	
Provide a good faith estimate, rounded to the nearest	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.	
\$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity	☐ Method A. Reporting amounts using LDA definitions only	
for lobbying activities on behalf of the client).	Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code	
	☐ Method C. Reporting amounts under section 162(e) of the Internal Revenue Code	
ignature Kathy Juado Inc	15/00 Bate	

CT 1.				**************************************	•	
	ent Name:			of Zeneca Inc.		
eag	gaged in lobby	ying on behalf	of the client d		y to reflect the general issue areas in which the registrant ig period. Using a separate page for each code, provide	
15.	. General iss . Specific La	sue area code obbying issues	<u>HCR</u>	(one per page)		
	Federal re	gulation of pr	rescription da	in Sa		
			~			
					·	
	٠.					
17.	. House(s) o	Congress and nt of Health &	l Federal agen & Human Ser	cies contacted	Cleck if None	
	To chart state	31 VI 210dia C	* 11 maines 2 m			
10	N F- 0					
18.		ach individual v	wbo acted as a	a lobbyist in this i		I
18.	Name of ca	ach individual v	who acted as a	a lobbyist in this i	Covered Official Position (if applicable)	Nex
18.			who acted as a	a lobbyist in this i		New No
18.	Name Iseman, V		who acted as a	a lobbyist in this i		<u> </u>
18.	Name Iseman, V	icki unoz, Kathy	who acted as a	a lobbyist in this i	Covered Official Position (if applicable)	No
18.	Name Iseman, V Jurado M	icki unoz, Kathy	who acted as a	a lobbyist in this i	Covered Official Position (if applicable)	No No
18.	Name Iseman, V Jurado M	icki unoz, Kathy	who acted as a	a lobbyist in this i	Covered Official Position (if applicable)	No No
18.	Name Iseman, V Jurado M	icki unoz, Kathy	who acted as a	a lobbyist in this i	Covered Official Position (if applicable)	No
18.	Name Iseman, V Jurado M	icki unoz, Kathy	who acted as a	a lobbyist in this i	Covered Official Position (if applicable)	No No
	Name Iseman, V Jurado M Schlesinge	icki unoz, Kathy er, Paul			Covered Official Position (if applicable)	No No
	Name Iseman, V Jurado M Schlesinge	icki unoz, Kathy er, Paul each foreiga er	ntiry in the spe	≈ific issues listed	Covered Official Position (if applicable) Asst Secretary, Department of Vetexans Affairs on line 16 above Check if None	No No
19.	Name Iseman, V Jurado M Schlesinge	icki unoz, Kathy er, Paul each foreiga er	ntiry in the spe		Covered Official Position (if applicable) Asst Secretary, Department of Vetexans Affairs on line 16 above Check if None	No No